Kureha Corporation
https://www.kureha.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kureha Corporation
Swiss Medtechs Contrast EU MDR ‘Chaos’ With Picture Of US Regulatory Efficiency
The ongoing failure of Swiss and European Commission decision makers to resolve the issue of Switzerland’s institutional agreement is hampering EU market access for Swiss innovators like IVDs company Abionic. More pressingly, the EU must address the wider issue of the MDR’s negative impact on innovation and start-ups, says Abionic co-founder Iwan Märki.
$100m+ China Biotech VC/PE Financings Return In July
Pyrotech Therapeutics and Worg Pharmaceuticals are among the few Chinese biotechs to have bagged fresh large funding round from venture capital and private equity investors over the past month.
Finance Watch: SPAC Deals Stumble, Layoffs Continue As Valuations Struggle To Recover
Aesther Healthcare Acquisition extended the deadline to merge with Ocean Biomedical, while Intrinsic Medicine no longer plans to go public by merging with a SPAC. In restructuring news, Otonomy begins liquidation, Celyad cuts last clinical program with cash running out and Clovis files for bankruptcy.
Finance Watch: Recent Upswing Turns Down, But Two Small IPOs Launch
Shuttle Pharmaceuticals and PaxMedica launch two small initial public offerings in the US as the market awaits a significant IPO. Also, Assertio closed a $70m follow-on offering, Codiak restructures and cuts jobs, and Vilya emerges with $50m in series A venture capital.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Kureha Chemical Industry Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice